Literature DB >> 25593469

Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation.

Keigo Suetani1, Chiaki Okuse1, Kazunari Nakahara1, Yosuke Michikawa1, Yohei Noguchi1, Midori Suzuki1, Ryo Morita1, Nozomi Sato1, Masaki Kato1, Fumio Itoh1.   

Abstract

AIM: To evaluate the need for thrombomodulin (rTM) therapy for disseminated intravascular coagulation (DIC) in patients with acute cholangitis (AC)-induced DIC.
METHODS: Sixty-six patients who were diagnosed with AC-induced DIC and who were treated at our hospital were enrolled in this study. The diagnoses of AC and DIC were made based on the 2013 Tokyo Guidelines and the DIC diagnostic criteria as defined by the Japanese Association for Acute Medicine, respectively. Thirty consecutive patients who were treated with rTM between April 2010 and September 2013 (rTM group) were compared to 36 patients who were treated without rTM (before the introduction of rTM therapy at our hospital) between January 2005 and January 2010 (control group). The two groups were compared in terms of patient characteristics at the time of DIC diagnosis (including age, sex, primary disease, severity of cholangitis, DIC score, biliary drainage, and anti-DIC drugs), the DIC resolution rate, DIC score, the systemic inflammatory response syndrome (SIRS) score, hematological values, and outcomes. Using logistic regression analysis based on multivariate analyses, we also examined factors that contributed to persistent DIC.
RESULTS: There were no differences between the rTM group and the control group in terms of the patients' backgrounds other than administration. DIC resolution rates on day 9 were higher in the rTM group than in the control group (83.3% vs 52.8%, P < 0.01). The mean DIC scores on day 7 were lower in the rTM group than in the control group (2.1 ± 2.1 vs 3.5 ± 2.3, P = 0.02). The mean SIRS scores on day 3 were significantly lower in the rTM group than in the control group (1.1 ± 1.1 vs 1.8 ± 1.1, P = 0.03). Mortality on day 28 was 13.3% in the rTM group and 27.8% in the control group; these rates were not significantly different (P = 0.26). Multivariate analysis identified only the absence of biliary drainage as significantly associated with persistent DIC (P < 0.01, OR = 12, 95%CI: 2.3-60). Although the difference did not reach statistical significance, primary diseases (malignancies) (P = 0.055, OR = 3.9, 95%CI: 0.97-16) and the non-use of rTM had a tendency to be associated with persistent DIC (P = 0.08, OR = 4.3, 95%CI: 0.84-22).
CONCLUSION: The add-on effects of rTM are anticipated in the treatment of AC-induced DIC, although biliary drainage for AC remains crucial.

Entities:  

Keywords:  Acute cholangitis; Anticoagulant therapy; Biliary drainage; Disseminated intravascular coagulation; Thrombomodulin

Mesh:

Substances:

Year:  2015        PMID: 25593469      PMCID: PMC4292285          DOI: 10.3748/wjg.v21.i2.533

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Endoscopic biliary drainage for severe acute cholangitis.

Authors:  E C Lai; F P Mok; E S Tan; C M Lo; S T Fan; K T You; J Wong
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

Review 2.  The cytoprotective protein C pathway.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.

Authors:  H Saito; I Maruyama; S Shimazaki; Y Yamamoto; N Aikawa; R Ohno; A Hirayama; T Matsuda; H Asakura; M Nakashima; N Aoki
Journal:  J Thromb Haemost       Date:  2006-10-13       Impact factor: 5.824

4.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

5.  Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Authors:  J Kienast; M Juers; C J Wiedermann; J N Hoffmann; H Ostermann; R Strauss; H-O Keinecke; B L Warren; S M Opal
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

6.  Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.

Authors:  Yoshihito Ogawa; Kazuma Yamakawa; Hiroshi Ogura; Takeyuki Kiguchi; Tomoyoshi Mohri; Yasushi Nakamori; Yasuyuki Kuwagata; Takeshi Shimazu; Toshimitsu Hamasaki; Satoshi Fujimi
Journal:  J Trauma Acute Care Surg       Date:  2012-05       Impact factor: 3.313

7.  Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes.

Authors:  Takashi Ito; Ko-ichi Kawahara; Kohji Okamoto; Shingo Yamada; Minetsugu Yasuda; Hitoshi Imaizumi; Yuko Nawa; Xiaojie Meng; Binita Shrestha; Teruto Hashiguchi; Ikuro Maruyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-03       Impact factor: 8.311

8.  TG13 flowchart for the management of acute cholangitis and cholecystitis.

Authors:  Fumihiko Miura; Tadahiro Takada; Steven M Strasberg; Joseph S Solomkin; Henry A Pitt; Dirk J Gouma; O James Garden; Markus W Büchler; Masahiro Yoshida; Toshihiko Mayumi; Kohji Okamoto; Harumi Gomi; Shinya Kusachi; Seiki Kiriyama; Masamichi Yokoe; Yasutoshi Kimura; Ryota Higuchi; Yuichi Yamashita; John A Windsor; Toshio Tsuyuguchi; Toshifumi Gabata; Takao Itoi; Jiro Hata; Kui-Hin Liau
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-01       Impact factor: 7.027

9.  Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.

Authors:  Kazuma Yamakawa; Satoshi Fujimi; Tomoyoshi Mohri; Hiroki Matsuda; Yasushi Nakamori; Tomoya Hirose; Osamu Tasaki; Hiroshi Ogura; Yasuyuki Kuwagata; Toshimitsu Hamasaki; Takeshi Shimazu
Journal:  Crit Care       Date:  2011-05-11       Impact factor: 9.097

10.  Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.

Authors:  Kazuma Yamakawa; Hiroshi Ogura; Satoshi Fujimi; Miki Morikawa; Yoshihito Ogawa; Tomoyoshi Mohri; Yasushi Nakamori; Yoshiaki Inoue; Yasuyuki Kuwagata; Hiroshi Tanaka; Toshimitsu Hamasaki; Takeshi Shimazu
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

View more
  4 in total

1.  Attempt for a Recombinant Thrombomodulin Alpha Treatment in a Rat Disseminated Intravascular Coagulation Model Using Yamakagashi (Rhabdophis tigrinus) Venom.

Authors:  Akihiko Yamamoto; Takashi Ito; Toru Hifumi
Journal:  Toxins (Basel)       Date:  2022-05-02       Impact factor: 5.075

2.  Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III.

Authors:  Satoshi Nakayama; Naoya Murashima
Journal:  Case Rep Med       Date:  2020-04-13

3.  Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis.

Authors:  Atsushi Okuda; Takeshi Ogura; Miyuki Imanishi; Akira Miyano; Nobu Nishioka; Kazuhide Higuchi
Journal:  Gut Liver       Date:  2018-07-15       Impact factor: 4.519

4.  Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation.

Authors:  Nozomi Morita; Kazunari Nakahara; Ryo Morita; Keigo Suetani; Yosuke Michikawa; Junya Sato; Kensuke Tsuji; Hiroki Ikeda; Kotaro Matsunaga; Tsunamasa Watanabe; Nobuyuki Matsumoto; Chiaki Okuse; Michihiro Suzuki; Fumio Itoh
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.